Licensing Opportunities

BaroFeron (Interferon beta-1b):
BaroFold is seeking a development partner for BaroFeron, an enhanced, second-generation Interferon beta-1b , using BaroFold’s PreEMT technology.

PreEMT Technology:
BaroFold is in the process of screening and selecting a single partner to develop a portfolio of enhanced, novel proteins that will address market opportunities not currently available with standard of care treatment. Proteins that are in later stages of clinical development with problems that can be addressed by PreEMT technologies will also be considered.

PreEMT Therapeutics Pipeline:
BaroFold will entertain development partners for its line of PreEMT therapeutics. Ideal partners are those that are currently in the Research & Development phase, and are looking for a portfolio approach to expanding biologic products in immunology indications.